Cisplatin is a highly effective chemotherapeutic agent that is widely used to treat solid organ malignancies. However, serious side effects have been associated with its use, such as bilateral, progressive, irreversible, dose-dependent neurosensory hearing loss. Current evidence indicates that cisplatin triggers the production of reactive oxygen species in target tissues in the inner ear. A var...

Cisplatin is a chemotherapeutical agent that is highly effective in the treatment of solid organ tumours, such as ovarian, testicular, bladder, non-small cell pulmonary, and head and neck tumours. The main side effects associated with the use of cisplatin are gastrointestinal toxicity, nephrotoxicity, myelotoxicity, peripheral neurotoxicity and ototoxicity. Ototoxic lesions cause bilateral neur...

BACKGROUND The purpose of this study was to assess the efficacy and toxicity of docetaxel, cisplatin/5-fluorouracil (TPF) induction chemotherapy and concomitant immunochemoradiotherapy with cetuximab and cisplatin in unresectable head and neck carcinoma. METHODS Treatment consisted of TPF induction chemotherapy (docetaxel 75 mg/m(2) day 2; cisplatin, 75 mg/m(2) day 2; and 5-fluorouracil 750 m...

A prominent circadian rhythm in the nephrotoxicity of a therapeutic dose of cis-diamminedichloroplatinum (cisplatin) is demonstrated in female Fischer rats. Rats were randomized to receive two doses of either cisplatin or 0.9% NaCl solution 14 days apart at the times of either high or low values in their circadian rhythm of urinary volume. Toxicity was assessed by measuring changes in body weig...

prevention of radiation-induced xerostomia in head and/or neck cancers in 21% (n ¼ 6), reduction of renal toxicity from cisplatin in 3% (n ¼ 1), and reduction of fatigue from cisplatin in 3% (n ¼ 1). The majority of patients (79%) experienced at least one adverse effect with the most common being nausea and vomiting, rash, and hypotension. Additional results will be presented.

BACKGROUND We investigated the efficacy and safety of S-1 and cisplatin with concurrent thoracic radiation (SCCR) over cisplatin alone plus concurrent thoracic radiation (CCR) for unresectable stage III non-small-cell lung cancer (NSCLC). METHODS Between January 2009 and November 2011, 40 eligible patients with NSCLC were included and divided randomly into two groups. Twenty patients received...

Despite the prevalent clinical applications of cisplatin, serious toxic side effects comprising reproductive toxicity confine its therapeutic efficacy. Thus, the current study explored the possible protective effect of captopril and telmisartan against cisplatin-induced testicular damage in rats. Captopril (100 mg/kg) and telmisartan (10 mg/kg) were orally administered for 15 days, whereas cisp...

Nephrotoxic drugs are responsible for approximately 20% of the episodes of acute kidney injury (AKI) in hospital and outpatient settings. Among elderly individuals, the incidence of drug-induced nephrotoxicity can be as high as 66%. Cisplatin (cis-diamminedichloroplatinum II CDDP) is an oncologic medication included in most chemotherapy regimens for solid or hematologic tumors. Cisplatin’s anti...

PURPOSE The majority of Egyptian patients with lung cancer present at a late stage of the disease. Bevacizumab/carboplatin/paclitaxel, as well as cisplatin plus pemetrexed, are both standard regimens for advanced non-squamous bronchogenic cancer. This study compares both regimens, in terms of efficacy and toxicity profile, in Egyptian patients. PATIENTS AND METHODS This is a randomized Phase ...

Background Cisplatin is a common platinum based chemotherapy drug that is commonly used for the treatment of the solid tumors. It is believed that this drug has nephrotoxic effects due to its oxidative action. Therefore, it is believed antioxidant agents such as vitamin...